ZINNAT TABLET 250 MG [SIN02365P]

Product Info

ZINNAT TABLET 250 MG

[SIN02365P]

4.1 Therapeutic indications
ZINNAT is an oral prodrug of the bactericidal cephalosporin antibiotic cefuroxime, which is resistant to most beta-lactamases and is active against a wide range of Gram-positive and Gram-negative organisms.

It is indicated for the treatment of infections caused by susceptible bacteria. Susceptibility to ZINNAT will vary with geography and time, and it should be used in accordance with local official antibiotic prescribing guidelines and local susceptibility data (see Section 5.1, Pharmacodynamics – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).

Indications include:
Upper respiratory tract infections (for example: ear, nose and throat infections, such as otitis media, sinusitis, tonsillitis and pharyngitis).

Lower respiratory tract infections (for example: pneumonia and acute exacerbations of chronic obstructive pulmonary disease).

Genito-urinary tract infections (for example: pyelonephritis, cystitis and urethritis).

Gonorrhoea, acute uncomplicated gonococcal urethritis and cervicitis.

Skin and soft tissue infections (for example: furunculosis, pyoderma and impetigo).

4.2 Posology and method of administration
The usual course of therapy is seven days (range five to ten days). The dose of ZINNAT that is selected to treat an individual infection should take into account:

• The expected pathogens and their likely susceptibility to ZINNAT

• The severity and the site of the infection

• The age, weight and renal function of the patient: as shown below.

The duration of therapy should be determined by the type of infection and the response of the patient, and should generally not be longer than recommended.

Dosage in adults and children weighing more than 40 kg:

Dosage in children weighing between 20–40 kg:

ZINNAT tablets should not be crushed or split and are therefore unsuitable for treatment of patients, such as younger children, who cannot swallow whole tablets. Therefore, ZINNAT suspension is recommended for patients who cannot swallow whole tablets.
When doses below 250 mg are required, ZINNAT FOR SUSPENSION 125mg/5ml should be used.

There is no experience of using ZINNAT in children under the age of 3 months.

Dosage in renal impairment:
Cefuroxime is primarily excreted by the kidneys. In patients with markedly impaired renal function, it is recommended that the dosage of cefuroxime be reduced to compensate for its slower excretion (see the table below).

Method of administration:
Oral use.
ZINNAT should be taken after food for optimum absorption.

4.3 Contraindications
Patients with known hypersensitivity to cephalosporin antibiotics.